LUNG CANCER RESISTANCE
Lung cancer: Scientists
find answer to resistance
Research
at the University of Southern Denmark
ark has revealed that a new combination of
clinically tested drugs inhibits the growth of tumors, thereby potentially
improving patients' survival

University of Southern Denmark Faculty of Health Sciences
IMAGE: The
research team of Professor Henrik Ditzel, University of Southern Denmark, has
revealed that a new combination of clinically tested drugs inhibits the growth
of tumors in lung cancer, thereby...
Credit:
University of Southern Denmark
Research
at the University of Southern Denmark has revealed that a new combination of
clinically tested drugs inhibits the growth of tumours, thereby potentially
improving patients' survival.
Scientists
at the University of Southern Denmark have found a new strategy for overcoming
the resistance, which many lung cancer patients develop towards a recent drug,
which can arrest the growth of tumours.
An
EGFR tyrosine kinase inhibitor is a targeted drug that is used to block a
special signal pathway (EGFR) in the cancer cells, thereby arresting tumour growth.
However, often the positive effect does not last. After about a year, the lung
cancer cells have found other ways to multiply, so many patients become
resistant to the treatment.
"We
investigated how the cancer cells evade the treatment. They do this in at least
10 different ways, and there is no denying that it complicates the challenge of
finding a subsequent treatment that, in the longer term, can stop tumour growth
and improve survival of lung cancer patients," says Professor and
Consultant Henrik Ditzel from the Department of Molecular Medicine at the
University of Southern Denmark and the Department of Oncology at Odense
University Hospital.
Common
factors for resistance
His
research group can now prove that there is a common mechansim for the cells
that develop resistance. The cells upgrade a different signal pathway (AKT),
resulting in elevated AKT activity in cell samples from lung cancer patients,
who no longer respond to treatment with tyrosine kinase inhibitors.
So
scientists (in cell cultures and in mice) tested a combination treatment using
an EGFR tyrosine kinase inhibitor and an AKT inhibitor, and the tests showed
that the tumour growth was arrested.
According
to Henrik Ditzel, it may not be very long before the results, which has just
been published in the highly regarded journal, Nature Communications
with PhD student Kirstine Jacobsen as first author, can change management of
lung cancer patients.
"An
approved drug already exists to inhibit AKT activities. So we are aiming very
soon at embarking on a clinical study, in which lung cancer patients, whose
malignant tumour has increased AKT, will be given a combination treatment using
the two known drugs at the same time. In the longer term, we hope that this
will prolong the lives of lung cancer patients, if we can combine several
treatments - in other words, turning them into a single treatment - instead of
administering different treatments in succession," says Henrik Ditzel.
·
Lung cancer is the leading cause of cancer
mortality in the world. The study looks at non-small cell lung cancer, which
accounts for virtually 80% of all cases of lung cancer.
·
The study was conducted in collaboration
with scientists and doctors from Barcelona and San Francisco.
Comments